Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT07279194 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

Efficacy and Safety of HDM1005 in Chinese Obesity or Overweight Patients Without Diabetes

StatusRecruiting
PhasePhase 3
Started
View on ClinicalTrials.gov ↗
Record status
This record was last updated December 12, 2025 (before its estimated September 20, 2026 completion). Its status may not reflect the trial's current state.

Record History

  1. Study First Submitted
This is a 56-week randomized, double blinded, parallel-controlled study evaluating the efficacy andsafety of the HDM1005 in patients with obesity or overweight. Eligible participants will be screened and randomized to different dose group of HDM1005 or the placebo group at a ratio of 1:1:1 , HDM1005 or placebo will be given once weekly for 52 weeks, following by a safety follow up of 4 weeks. All participants received a lifestyle intervention that involved counselling on diet and physical activity.
Trial Details
NCT Number NCT07279194
Lead Sponsor Hangzhou Zhongmei Huadong Pharmaceutical Co., Ltd.
Conditions
(from sponsor)		 Obesity & Overweight
Related terms Obesity, Overweight
Enrollment 825 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov